Levine A C, Kirschenbaum A, Kaplan P, Droller M A, Gabrilove J L
Department of Medicine, Mount Sinai School of Medicine, New York, New York.
Urology. 1989 Jul;34(1):10-3. doi: 10.1016/0090-4295(89)90147-7.
We studied serum prostate-specific antigen levels in 12 men with benign prostatic hypertrophy treated with a long-acting GnRH analogue, leuprolide, 1 mg (0.2 mL) sc. daily for six months. The average decrease in prostate size measured by ultrasound was 45 percent after six months with concomitant improvement in the obstructive symptoms of prostatism. There was a steady decline in serum PSA levels which paralleled the decrease in prostate size. One patient who discontinued treatment after six months demonstrated both a regrowth of his prostate and a rise in serum PSA levels to pretreatment levels four months post-discontinuation of treatment. We conclude that treatment with a GnRH analogue caused reversible involution of prostatic epithelial cells with parallel effects on serum PSA levels. Consideration of the initial prostate size together with the serum PSA levels can help predict the response to medical castration in men with BPH.
我们研究了12名患有良性前列腺增生的男性患者，他们接受了长效促性腺激素释放激素（GnRH）类似物亮丙瑞林治疗，剂量为1毫克（0.2毫升），皮下注射，每日一次，共六个月。六个月后，通过超声测量，前列腺平均缩小了45%，同时前列腺增生梗阻症状得到改善。血清前列腺特异性抗原（PSA）水平持续下降，与前列腺大小的减小相平行。一名患者在六个月后停止治疗，在停药四个月后，其前列腺出现再生，血清PSA水平回升至治疗前水平。我们得出结论，GnRH类似物治疗导致前列腺上皮细胞可逆性萎缩，同时对血清PSA水平产生影响。综合考虑初始前列腺大小和血清PSA水平有助于预测良性前列腺增生男性患者对药物去势治疗的反应。
